Pandey Anita, Ezemenari Susan, Liaukovich Maksim, Richard Ivan, Boris Avezbakiyev
Department of Hematology and Oncology, Brookdale University Hospital, Medical Center, Brooklyn, USA.
Case Rep Oncol Med. 2018 Oct 17;2018:5985131. doi: 10.1155/2018/5985131. eCollection 2018.
Hepatitis B virus (HBV) infection is common across the world, especially in Asia, Africa, Southern Europe, and Latin America. The association of HBV infection in patients suffering from different oncological conditions is well established. Many cases of HBV reactivation have been reported in patients on immunosuppressive chemotherapy and in patients undergoing hematopoietic bone marrow transplantations. Only one case has been reported so far of HBV reactivation in a patient treated with programmed cell death receptor 1 (PD-1) checkpoint inhibitors in the setting of HIV status. We report a case of a 51-year-old male, former smoker, diagnosed with stage IV poorly differentiated adenocarcinoma of the lung, and started on pembrolizumab, who developed reactivation of chronic hepatitis requiring antiviral therapy.
乙型肝炎病毒（HBV）感染在全球范围内都很常见，尤其是在亚洲、非洲、南欧和拉丁美洲。HBV感染与患有不同肿瘤疾病的患者之间的关联已得到充分证实。免疫抑制化疗患者和接受造血骨髓移植的患者中已报告了许多HBV再激活病例。迄今为止，仅报告了1例在HIV感染状态下接受程序性细胞死亡受体1（PD-1）检查点抑制剂治疗的患者发生HBV再激活的病例。我们报告了1例51岁男性，既往吸烟者，被诊断为IV期低分化肺腺癌，开始使用派姆单抗治疗，该患者发生了慢性肝炎再激活，需要抗病毒治疗。
